Literature DB >> 24313835

A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR.

Sachin Surade1, Nancy Ty2, Narin Hengrung1, Benoit Lechartier3, Stewart T Cole3, Chris Abell2, Tom L Blundell1.   

Abstract

A structure-guided fragment-based approach was used to target the lipophilic allosteric binding site of Mycobacterium tuberculosis EthR. This elongated channel has many hydrophobic residues lining the binding site, with few opportunities for hydrogen bonding. We demonstrate that a fragment-based approach involving the inclusion of flexible fragments in the library leads to an efficient exploration of chemical space, that fragment binding can lead to an extension of the cavity, and that fragments are able to identify hydrogen-bonding opportunities in this hydrophobic environment that are not exploited in Nature. In the present paper, we report the identification of a 1 μM affinity ligand obtained by structure-guided fragment linking.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24313835     DOI: 10.1042/BJ20131127

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  8 in total

Review 1.  Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry.

Authors:  Tom L Blundell
Journal:  IUCrJ       Date:  2017-06-29       Impact factor: 4.769

2.  Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.

Authors:  Petar O Nikiforov; Michal Blaszczyk; Sachin Surade; Helena I Boshoff; Andaleeb Sajid; Vincent Delorme; Nathalie Deboosere; Priscille Brodin; Alain R Baulard; Clifton E Barry; Tom L Blundell; Chris Abell
Journal:  ACS Chem Biol       Date:  2017-04-05       Impact factor: 5.100

3.  Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.

Authors:  Judith E Unterlass; Arnaud Baslé; Timothy J Blackburn; Julie Tucker; Céline Cano; Martin E M Noble; Nicola J Curtin
Journal:  Oncotarget       Date:  2016-08-22

4.  Using Fragment-Based Approaches to Discover New Antibiotics.

Authors:  Bas Lamoree; Roderick E Hubbard
Journal:  SLAS Discov       Date:  2018-07       Impact factor: 3.341

5.  Reversing allosteric communication: From detecting allosteric sites to inducing and tuning targeted allosteric response.

Authors:  Wei-Ven Tee; Enrico Guarnera; Igor N Berezovsky
Journal:  PLoS Comput Biol       Date:  2018-06-18       Impact factor: 4.475

6.  Analysis of tractable allosteric sites in G protein-coupled receptors.

Authors:  Amanda E Wakefield; Jonathan S Mason; Sandor Vajda; György M Keserű
Journal:  Sci Rep       Date:  2019-04-16       Impact factor: 4.379

7.  A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.

Authors:  Petar O Nikiforov; Sachin Surade; Michal Blaszczyk; Vincent Delorme; Priscille Brodin; Alain R Baulard; Tom L Blundell; Chris Abell
Journal:  Org Biomol Chem       Date:  2016-01-25       Impact factor: 3.876

8.  Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach.

Authors:  Grace Mugumbate; Vitor Mendes; Michal Blaszczyk; Mohamad Sabbah; George Papadatos; Joel Lelievre; Lluis Ballell; David Barros; Chris Abell; Tom L Blundell; John P Overington
Journal:  Front Pharmacol       Date:  2017-09-26       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.